Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NPX-267 by NextPoint Therapeutics for Prostate Cancer: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...
NPX-267 by NextPoint Therapeutics for Colorectal Cancer: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
NPX-267 by NextPoint Therapeutics for Cervical Cancer: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...
NPX-267 by NextPoint Therapeutics for Endometrial Cancer: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
NPX-267 by NextPoint Therapeutics for Osteosarcoma: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I...
NPX-267 by NextPoint Therapeutics for Renal Cell Carcinoma: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...
NPX-267 by NextPoint Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
NPX-267 by NextPoint Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
NPX-267 by NextPoint Therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....
NPX-267 by NextPoint Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
NPX-267 by NextPoint Therapeutics for Gastric Cancer: Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
NPX-267 by NextPoint Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
NPX-267 is under clinical development by NextPoint Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...